Long-term survival rates of patients undergoing vitrectomy for diabetic retinopathy in an Australian population: a population-based audit.


Journal

Clinical & experimental ophthalmology
ISSN: 1442-9071
Titre abrégé: Clin Exp Ophthalmol
Pays: Australia
ID NLM: 100896531

Informations de publication

Date de publication:
07 2019
Historique:
received: 29 10 2018
revised: 08 01 2019
accepted: 09 01 2019
pubmed: 22 1 2019
medline: 1 8 2020
entrez: 22 1 2019
Statut: ppublish

Résumé

Five-year survival rates in patients undergoing vitrectomy for diabetic retinopathy (DR) vary from 68% to 95%. No study has been conducted in an Australian population. We aimed to determine the survival rates of patients undergoing diabetic vitrectomy in an Australian population. Retrospective audit, tertiary centre hospitals and private practices. All individuals in South Australia and the Northern Territory who underwent their first vitrectomy for diabetic complications between January 1, 2007 and December 31, 2011. An audit of all eligible participants has been completed previously. Survival status as of July 6, 2018 and cause of death were obtained using SA/NT DataLink. Kaplan-Meier survival curves and multivariate cox-regressions were used to analyse survival rates and identify risk factors for mortality. Five-, seven- and nine-year survival rates. The 5-, 7- and 9-year survival rates were 84.4%, 77.9% and 74.7%, respectively. The most common cause of death was cardiovascular disease. Associated with increased mortality independent of age were Indigenous ethnicity (HR = 2.04, 95% confidence interval [CI]: 1.17-3.57, P = 0.012), chronic renal failure (HR = 1.76, 95% CI: 1.07-2.89, P = 0.026) and renal failure requiring dialysis (HR = 2.32, 95% CI: 1.25-4.32, P = 0.008). Long-term survival rates after diabetic vitrectomy in Australia are similar to rates reported in other populations. Indigenous ethnicity and chronic renal failure were the most significant factors associated with long-term mortality. This information can guide allocation of future resources to improve the prognosis of these high risk groups.

Sections du résumé

IMPORTANCE
Five-year survival rates in patients undergoing vitrectomy for diabetic retinopathy (DR) vary from 68% to 95%. No study has been conducted in an Australian population.
BACKGROUND
We aimed to determine the survival rates of patients undergoing diabetic vitrectomy in an Australian population.
DESIGN
Retrospective audit, tertiary centre hospitals and private practices.
PARTICIPANTS
All individuals in South Australia and the Northern Territory who underwent their first vitrectomy for diabetic complications between January 1, 2007 and December 31, 2011.
METHODS
An audit of all eligible participants has been completed previously. Survival status as of July 6, 2018 and cause of death were obtained using SA/NT DataLink. Kaplan-Meier survival curves and multivariate cox-regressions were used to analyse survival rates and identify risk factors for mortality.
MAIN OUTCOME MEASURES
Five-, seven- and nine-year survival rates.
RESULTS
The 5-, 7- and 9-year survival rates were 84.4%, 77.9% and 74.7%, respectively. The most common cause of death was cardiovascular disease. Associated with increased mortality independent of age were Indigenous ethnicity (HR = 2.04, 95% confidence interval [CI]: 1.17-3.57, P = 0.012), chronic renal failure (HR = 1.76, 95% CI: 1.07-2.89, P = 0.026) and renal failure requiring dialysis (HR = 2.32, 95% CI: 1.25-4.32, P = 0.008).
CONCLUSIONS AND RELEVANCE
Long-term survival rates after diabetic vitrectomy in Australia are similar to rates reported in other populations. Indigenous ethnicity and chronic renal failure were the most significant factors associated with long-term mortality. This information can guide allocation of future resources to improve the prognosis of these high risk groups.

Identifiants

pubmed: 30663192
doi: 10.1111/ceo.13466
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

598-604

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : ErratumIn

Informations de copyright

© 2019 Royal Australian and New Zealand College of Ophthalmologists.

Auteurs

Ebony Liu (E)

Department of Ophthalmology, Flinders Medical Centre, Flinders University, Adelaide, South Australia, Australia.

Jose Estevez (J)

Department of Ophthalmology, Flinders Medical Centre, Flinders University, Adelaide, South Australia, Australia.

Georgia Kaidonis (G)

Department of Ophthalmology, Flinders Medical Centre, Flinders University, Adelaide, South Australia, Australia.

Mark Hassall (M)

Department of Ophthalmology, Flinders Medical Centre, Flinders University, Adelaide, South Australia, Australia.

Russell Phillips (R)

Department of Ophthalmology, Flinders Medical Centre, Flinders University, Adelaide, South Australia, Australia.
Department of Ophthalmology, Royal Adelaide Hospital, University of Adelaide, Adelaide, South Australia, Australia.

Grant Raymond (G)

Department of Ophthalmology, Royal Adelaide Hospital, University of Adelaide, Adelaide, South Australia, Australia.

Niladri Saha (N)

Department of Ophthalmology, Flinders Medical Centre, Flinders University, Adelaide, South Australia, Australia.
Eyemedics, Wayville, South Australia, Australia.

George H C Wong (GHC)

Marion Road Eye Clinic, Adelaide, South Australia, Australia.

Jagjit Gilhotra (J)

Department of Ophthalmology, Royal Adelaide Hospital, University of Adelaide, Adelaide, South Australia, Australia.
Department of Ophthalmology, Queen Elizabeth Hospital, Adelaide, South Australia, Australia.

Kathryn Burdon (K)

Department of Ophthalmology, Flinders Medical Centre, Flinders University, Adelaide, South Australia, Australia.
Department of Cancer, Genetics and Immunology, Menzies Research Institute, University of Tasmania, Hobart, Tasmania, Australia.

John Landers (J)

Department of Ophthalmology, Flinders Medical Centre, Flinders University, Adelaide, South Australia, Australia.

Tim Henderson (T)

Department of Ophthalmology, Alice Springs Hospital, Alice Springs, Northern Territory, Australia.

Henry Newland (H)

Department of Ophthalmology, Royal Adelaide Hospital, University of Adelaide, Adelaide, South Australia, Australia.

Stewart Lake (S)

Department of Ophthalmology, Flinders Medical Centre, Flinders University, Adelaide, South Australia, Australia.
Eyemedics, Wayville, South Australia, Australia.

Jamie E Craig (JE)

Department of Ophthalmology, Flinders Medical Centre, Flinders University, Adelaide, South Australia, Australia.
Eyemedics, Wayville, South Australia, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH